BridgeBio Oncology Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BBOT Nasdaq 2836 bbotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook - Sep 12th, 2026 1:40 am
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Sep 11th, 2026 3:37 am
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers - Sep 8th, 2026 2:05 pm
BBOT to Participate in Upcoming Investor Healthcare Conferences - Sep 1st, 2026 2:05 pm
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 11th, 2026 2:40 pm
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - Aug 11th, 2026 2:05 pm
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Jun 30th, 2026 7:06 am
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - May 17th, 2026 12:25 pm
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - May 17th, 2026 12:18 pm
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet - May 15th, 2026 5:02 pm
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - May 15th, 2026 4:56 pm
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares - May 15th, 2026 4:50 pm
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress - May 12th, 2026 3:03 pm
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More - May 11th, 2026 5:58 am
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics - Apr 24th, 2026 4:46 am
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 - Apr 22nd, 2026 2:05 pm
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - Apr 22nd, 2026 7:00 am